Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of eastern cooperative group and cancer and leukemia group B studies
- 1 October 1990
- Vol. 66 (7) , 1621-1629
- https://doi.org/10.1002/1097-0142(19901001)66:7<1621::aid-cncr2820660729>3.0.co;2-g
Abstract
In premenopausal women with metastatic breast cancer, differences in survival curves early during follow-up can be misleading. The authors therefore analyzed long-term survival in 378 patients, entered in three randomized trials, started between 1973 and 1978. Combined data from the three trials were used to increase the power for identifying prognostic variables. Cancer and Leukemia Group B (CALGB) trial 7382 randomized patients to oophorectomy plus either cyclophosphamide or combination chemotherapy or observation. Eastern Cooperative Oncology Group (ECOG) 2174 randomized patients who had not progressed 3 months after oophorectomy to combination chemotherapy or combination chemotherapy or observation. Trial ECOG 2177 randomized estrogen receptor (ER) positive or ER-unknown patients to oophorectomy plus combination chemotherapy or immediate combination chemotherapy, and ER-negative patients were directly assigned to combination chemotherapy. Hence ER-negative patients need not have been healthy enough to be randomized to oophorectomy. With only 14% of the patients still alive, median survival on the three studies was 30, 24, and 28 months. The median survival of individual treatments changed noticeably in ECOG 2174 and ECOG 2177 with long-term follow-up. At this time there are no differences in survival between randomized regimens in any of the three trials. In a multivariate model, factors associated with significantly poorer survival were visceral-dominant disease, nodal metastases, breast metastases, age younger than 45 years, ER negativity, and not receiving chemotherapy immediately after oophorectomy. This treatment difference was thus not due to imbalances in the prognostic variables used in the model, but it may be due to imbalances of unknown prognostic factors or differences in patient selection.This publication has 17 references indexed in Scilit:
- An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy A later analysisAmerican Journal of Clinical Oncology, 1982
- Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal womenAmerican Journal of Clinical Oncology, 1982
- Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. A study by cancer and leukemia group BCancer, 1979
- Sample size and power determination for stratified clinical trialsJournal of Statistical Computation and Simulation, 1978
- An Evaluation of Early or Delayed Adjuvant Chemotherapy in Premenopausal Patients with Advanced Breast Cancer Undergoing OophorectomyNew England Journal of Medicine, 1977
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Extended survival and remission rates in metastatic breast cancerCancer, 1971
- Hormone therapy in inoperable breast cancerCancer, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- An evaluation of therapeutic surgical castration in the treatment of metastatic, recurrent, and primary inoperable mammary carcinoma in women. An analysis of 191 patientsCancer, 1958